Get the Stockscreener App
1.57
6.08%
0.09
Pre-market:
1.57
Autolus Therapeutics Plc Adr stock is traded at $1.57, with a volume of 3.58M.
It is up +6.08% in the last 24 hours and up +11.35% over the past month.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
See More
Previous Close:
$1.48
Open:
$1.49
24h Volume:
3.58M
Relative Volume:
0.93
Market Cap:
$417.84M
Revenue:
-
Net Income/Loss:
$-208.38M
P/E Ratio:
-1.3083
EPS:
-1.2
Net Cash Flow:
$-156.57M
1W Performance:
+14.60%
1M Performance:
+11.35%
6M Performance:
-24.88%
1Y Performance:
-48.52%
1-Day Range:
$1.46
$1.61
1-Week Range:
$1.31
$1.61
52-Week Range:
$1.105
$3.11
Autolus Therapeutics Plc Adr Stock (AUTL) Company Profile
Name
Autolus Therapeutics Plc Adr
Sector
Industry
Phone
44 20 3829 6230
Address
THE MEDIAWORKS, LONDON
Compare AUTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUTL
Autolus Therapeutics Plc Adr
|
1.57 | 393.89M | 0 | -208.38M | -156.57M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Autolus Therapeutics Plc Adr Stock (AUTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Upgrade | Goldman | Neutral → Buy |
| Nov-15-24 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Mar-27-23 | Resumed | Wells Fargo | Overweight |
| Mar-17-23 | Initiated | Bryan Garnier | Buy |
| Jun-14-21 | Upgrade | Jefferies | Hold → Buy |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | JP Morgan | Overweight |
| Jul-22-20 | Initiated | SunTrust | Buy |
| Apr-22-20 | Initiated | Mizuho | Buy |
| Sep-23-19 | Initiated | Needham | Buy |
| May-17-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-24-18 | Initiated | H.C. Wainwright | Buy |
View All
Autolus Therapeutics Plc Adr Stock (AUTL) Latest News
Check Out Autolus Therapeutics plc ADR (AUTL)’s Trade Data Rather Than the Analysts’ Views - Setenews
Cetera Investment Advisers Has $1.41 Million Position in Autolus Therapeutics PLC Sponsored ADR $AUTL - Defense World
An analyst sees good growth prospects for Autolus Therapeutics plc ADR (AUTL) - Setenews
Taking on analysts’ expectations and winning: EON Resources Inc (EONR) - Setenews
Ready to Jump After Recent Trade: BitMine Immersion Technologies Inc (BMNR) - Setenews
Iterum Therapeutics Plc (ITRM) Performance and Fundamentals Dashboard tells a completely different story - Setenews
Taking on analysts’ expectations and winning: enVVeno Medical Corporation (NVNO) - Setenews
Check out these key findings about Streamex Corp (STEX) - Setenews
This trade activity should not be overlooked: ETHZilla Corp (ETHZ) - Setenews
A better buy-in window may exist right now for Centessa Pharmaceuticals plc ADR (CNTA) - Setenews
How does Advanced Biomed Inc (ADVB) change from a tortoise to a hare? - Setenews
A look into Mobile health Network Solutions (MNDR)’s deeper side - Setenews
Traws Pharma Inc (TRAW) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
Taking on analysts’ expectations and winning: Gelteq Ltd (GELS) - Setenews
Wall Street analysts’ outlook for Amaze Holdings Inc (AMZE) - Setenews
Is Autolus Therapeutics PLC (AUTL) One of the Fastest-Growing Penny Stocks to Buy Now? - Finviz
NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹ - GlobeNewswire Inc.
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
A new trading data show Ashford Hospitality Trust Inc (AHT) is showing positive returns. - Setenews
Taking on analysts’ expectations and winning: Houston American Energy Corp (HUSA) - Setenews
Does Klotho Neurosciences Inc (KLTO) offer a good opportunity for investors? - Setenews
The time has not yet come to remove your chips from the table: Psyence Biomedical Ltd (PBM) - Setenews
Newsmax Inc (NMAX) can make a big difference with a little luck - Setenews
Check Out Dolly Varden Silver Corp (DVS)’s Trade Data Rather Than the Analysts’ Views - Setenews
Views of Wall Street’s Leading Experts on Viomi Technology Co Ltd ADR - Setenews
Are Smart Investors Making the Right Decision? Empery Digital Inc (EMPD) - Setenews
Wall Street analysts’ outlook for Picard Medical Inc (PMI) - Setenews
Autolus Therapeutics plc ADR (AUTL) is looking forward to a strong quarter - Setenews
Views of Wall Street’s Leading Experts on Twin Vee PowerCats Co - Setenews
This trade activity should not be overlooked: Amaze Holdings Inc (AMZE) - Setenews
Wall Street analysts’ outlook for Cypherpunk Technologies Inc (CYPH) - Setenews
William Blair Issues Pessimistic Forecast for AUTL Earnings - Defense World
There is no doubt that Cycurion Inc (CYCU) ticks all the boxes. - Setenews
Check Out SIGA Technologies Inc (SIGA)’s Trade Data Rather Than the Analysts’ Views - Setenews
How Autolus Therapeutics plc (Common Stock) (6A3A) stock moves on employment data2025 Price Targets & Weekly High Momentum Picks - newser.com
Top investors say Autolus Therapeutics plc ADR (AUTL) ticks everything they need - Setenews
Pony AI Inc. ADR (PONY) can make a big difference with a little luck - Setenews
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates? - TradingView
A Look at VivoPower International PLC (VVPR) Shares in the Recent Past Indicates Growth - Setenews
Cash from investing activities of Autolus Therapeutics Plc Sponsored ADR – HAM:6A3A - TradingView
Autolus Therapeutics Plc Sponsored ADR Statistics – HAM:6A3A - TradingView
A significant driver of top-line growth: Autolus Therapeutics plc ADR (AUTL) - setenews.com
Cardlytics Inc (CDLX) is looking forward to a strong quarter - setenews.com
Can Autolus Therapeutics plc Depositary Receipt rally from current levelsWeekly Investment Recap & Weekly Watchlist of Top Performers - newser.com
Q3 EPS Estimate for Autolus Therapeutics Lifted by Analyst - Defense World
Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025 - Barchart.com
What is Structure Therapeutics Inc ADR (GPCR) Stock Return on Shareholders’ Capital? - Setenews
Stocks of OneMedNet Corp (ONMD) are poised to climb above their peers - Setenews
What RSI levels show for Autolus Therapeutics plc (Common Stock) (6A3A) stockBear Alert & Fast Moving Stock Trade Plans - newser.com
First patient dosed in Autolus’ phase 1 trial for multiple sclerosis By Investing.com - Investing.com South Africa
First patient dosed in Autolus’ phase 1 trial for multiple sclerosis - Investing.com
Autolus Therapeutics Plc Adr Stock (AUTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):